Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439475 | 0.87 | KDM4E (0.57) | ALDH1A1KDM4ETDP1MEN1MAPT | |
| SCHEMBL17080193 | 0.84 | KDM4E (0.75) | ALDH1A1KDM4ETDP1MEN1MAPT | |
| SCHEMBL29441695 | 0.84 | KDM4E (0.75) | ALDH1A1KDM4ETDP1MEN1MAPT | |
| SCHEMBL4436373 | 0.84 | ALDH1A1 (0.56) | ALDH1A1KDM4ETDP1MEN1MAPT | |
| SCHEMBL3381158 | 0.83 | KDM4E (1.00) | ALDH1A1KDM4ETDP1MAPTHPGD | |
| SCHEMBL3409694 | 0.83 | ABL1 (0.60) | ALDH1A1KDM4ETDP1SLC6A2SLC6A4 | |
| SCHEMBL2032649 | 0.82 | KDM4E (0.71) | ALDH1A1KDM4ETDP1MEN1MAPT | |
| Hydrochloric Acid SCHEMBL15227699 | 0.82 | ABL1 (0.58) | ALDH1A1KDM4ETDP1SLC6A2SLC6A4 | |
| SCHEMBL3998999 | 0.82 | KDM4E (0.71) | ALDH1A1KDM4ETDP1MEN1MAPT | |
| Bromide SCHEMBL10675654 | 0.82 | KDM4E (0.71) | ALDH1A1KDM4ETDP1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937614-A1 | IRON CATALYZED CROSS-COUPLING REACTIONS OF IMIDOYL DERIVATIVES | Arcadia Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | ACADIA PHARMACEUTICALS | 2007-05-10 | — | — | US | disclosed |
| WO-2007047776-A1 | IRON CATALYZED CROSS-COUPLING REACTIONS OF IMIDOYL DERIVATIVES | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-6103715-A | COMPOUNDS THAT BIND TO THE DOPAMINE D4 RECEPTOR AND THEIR USE AS ANXIOLYTIC AGENTS, TREATMENT FOR SCHIZOPHRENIA, AND DRUG SCREENING; SIDE EFFECT REDUCTIOON | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-08-15 | — | — | US | disclosed |
| EP-0797577-B1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMA (CA) | 2000-07-26 | — | — | EP | disclosed |
| US-5849734-A | Muscarinic receptor ligands | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-12-15 | — | — | US | disclosed |
| US-5798350-A | TRICYCLIC DIBENZ(B,F)OXEPINES AND DIBENZO(B,F)THIEPINES FOR TREATING SCHIZOPHRENIA AND ANXIETY | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1998-08-25 | — | — | US | disclosed |
| US-5703072-A | TREATMENT OF SCHIZOPHRENIA AND ANXIETY | ALLELIX BIOPHARMACEUTICALS (CA) | 1997-12-30 | — | — | US | disclosed |
| US-5674877-A | TREATMENT OF PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1997-10-07 | — | — | US | disclosed |
| EP-0797577-A1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | Allelix Biopharmaceuticals Inc. (CA) | 1997-10-01 | — | — | EP | disclosed |
| EP-0736024-A1 | N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS | Allelix Biopharmaceuticals Inc. (CA) | 1996-10-09 | — | — | EP | disclosed |
| US-5561127-A | TREATING ANXIETY, SCHIZOPHRENIA | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1996-10-01 | — | — | US | disclosed |
| US-5538965-A | TREATMENT OF PSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA AND ANXIETY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-07-23 | — | — | US | disclosed |
| WO-1996019479-A1 | MUSCARINIC RECEPTOR LIGANDS | ALLELIX BIOPHARMACEUTICALS INC. (US) | 1996-06-27 | — | — | WO | disclosed |
| WO-1996018630-A1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995017400-A1 | N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | SDHB, TFRC, SLC40A1 | ALDH1A1 1576/4885KDM4E 1976/4885TDP1 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.